Virbac: Termination of the liquidity contract
TERMINATION OF THE LIQUIDITY CONTRACT
See the original post here:
Virbac: Termination of the liquidity contract
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Read more:
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on July 8, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 19,200 shares of its common stock to six new employees.
See the rest here:
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Oxurion provides clarification on the agenda of the extraordinary general shareholders’ meeting to be held on 24 July 2024
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024
The rest is here:
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory…
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC)
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter to stockholders highlighting recent achievements, growth plans, and consideration of a potential share buyback.
Go here to read the rest:
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL
Go here to read the rest:
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Spectral Medical Inc. Announces Change to Auditor
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that MNP LLP (“MNP”) have today been appointed as the auditors of the Company following the decision by PricewaterhouseCoopers LLP (“PwC”) to resign as the auditor of Spectral (the “Effective Date”). The resignation of PwC as the auditor of Spectral and the appointment of MNP as auditor of Spectral were considered and approved by the Finance & Audit Committee and the board of directors.
See more here:
Spectral Medical Inc. Announces Change to Auditor
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California.
See more here:
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Continue reading here:
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024